Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy

Abstract Background We have shown that an Akt inhibitor, MK2206, reduces hepatocellular carcinoma (HCC) proliferation. To further delineate MK2206, we sought to investigate the Notch1 pathway and hypothesize that MK2206 treatment will result in Notch1 inhibition with either subsequent or parallel Ak...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of surgery 2016-04, Vol.211 (4), p.755-760
Main Authors: Sokolowski, Kevin M., M.D, Balamurugan, Mariappan, Ph.D, Kunnimalaiyaan, Selvi, M.S, Wilson, Jacob, B.S, Gamblin, Thomas Clark, M.D., M.S., M.B.A., F.A.C.S, Kunnimalaiyaan, Muthusamy, Ph.D
Format: Article
Language:English
Subjects:
Akt
Blotting, Western
Carcinoma, Hepatocellular - pathology
Cell Line, Tumor
Cell Proliferation - drug effects
Cell Survival - drug effects
Clinical trials
Dual target
Hepatocellular carcinoma
Heterocyclic Compounds, 3-Ring - pharmacology
Humans
Kinases
Liver cancer
Liver Neoplasms - pathology
MK2206
Mortality
Notch
Phosphorylation
Proto-Oncogene Proteins c-akt - antagonists & inhibitors
Receptor, Notch1 - metabolism
Signal Transduction - drug effects
Studies
Surgery
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c448t-88641e2976d9e29918f4335dad215ba1072a44ba45381a26f6c3ec46ab2ecb163
cites cdi_FETCH-LOGICAL-c448t-88641e2976d9e29918f4335dad215ba1072a44ba45381a26f6c3ec46ab2ecb163
container_end_page 760
container_issue 4
container_start_page 755
container_title The American journal of surgery
container_volume 211
creator Sokolowski, Kevin M., M.D
Balamurugan, Mariappan, Ph.D
Kunnimalaiyaan, Selvi, M.S
Wilson, Jacob, B.S
Gamblin, Thomas Clark, M.D., M.S., M.B.A., F.A.C.S
Kunnimalaiyaan, Muthusamy, Ph.D
description Abstract Background We have shown that an Akt inhibitor, MK2206, reduces hepatocellular carcinoma (HCC) proliferation. To further delineate MK2206, we sought to investigate the Notch1 pathway and hypothesize that MK2206 treatment will result in Notch1 inhibition with either subsequent or parallel Akt suppression. Methods HCC cell lines were treated with various concentrations of MK2206. Cell proliferation was determined via real-time live cell imaging. Knockdown of Notch1 was used to observe interaction between Notch1 and pAkt. Cell lysates were analyzed via Western blotting for Notch and Akt pathway targets. Results After treatment with MK2206 (up to 2 μM), there was a 60% reduction in cell viability at 48 hours with a concomitant reduction in Notch1 expression. Knockdown of Notch1 in HCC cell lines correlated with reduction in Akt phosphorylation. Conclusions MK2206 inhibits both the PI3-K/Akt and Notch1 pathways. Therefore, further characterization of MK2206 comparing the 2 pathways is warranted and the effect of dual targeting in HCC.
doi_str_mv 10.1016/j.amjsurg.2015.11.029
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1774530732</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0002961016300125</els_id><sourcerecordid>3993006171</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-88641e2976d9e29918f4335dad215ba1072a44ba45381a26f6c3ec46ab2ecb163</originalsourceid><addsrcrecordid>eNqFkl2L1TAQhoso7nH1JygBb7xpzSRpm3qhLItfsCj4cR3SdLon3bbpJql4_r2p56iwN0JgSHjmncm8k2VPgRZAoXo5FHoawuqvC0ahLAAKypp72Q5k3eQgJb-f7SilLG8qoGfZoxCGdAUQ_GF2xipZUuB8l91-cSMS15OLm0jsvLetjdbNJJ1PLpo9EPy5eAxhe7Qz2eOiozM4juuoPTHaGzu7Sb8ii4s4R6tH4jfJ3nnSrekWtb_GiB2Je_R6OTzOHvR6DPjkFM-z7-_efrv8kF99fv_x8uIqN0LImEtZCUDW1FXXpNCA7AXnZac7BmWrgdZMC9FqUXIJmlV9ZTgaUemWoWmh4ufZi6Pu4t3tiiGqyYatcT2jW4OCuk65tOYsoc_voINb_Zy6-01JkUqUiSqPlPEuBI-9WrydtD8ooGrzRA3q5InaPFEAKnmS8p6d1Nd2wu5v1h8TEvDmCGAaxw-LXgVjcTbYWY8mqs7Z_5Z4fUfBjHa2Ro83eMDw7zcqMEXV120xtr1IY0o7wUr-C0FktN8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1774843815</pqid></control><display><type>article</type><title>Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy</title><source>ScienceDirect Journals</source><creator>Sokolowski, Kevin M., M.D ; Balamurugan, Mariappan, Ph.D ; Kunnimalaiyaan, Selvi, M.S ; Wilson, Jacob, B.S ; Gamblin, Thomas Clark, M.D., M.S., M.B.A., F.A.C.S ; Kunnimalaiyaan, Muthusamy, Ph.D</creator><creatorcontrib>Sokolowski, Kevin M., M.D ; Balamurugan, Mariappan, Ph.D ; Kunnimalaiyaan, Selvi, M.S ; Wilson, Jacob, B.S ; Gamblin, Thomas Clark, M.D., M.S., M.B.A., F.A.C.S ; Kunnimalaiyaan, Muthusamy, Ph.D</creatorcontrib><description>Abstract Background We have shown that an Akt inhibitor, MK2206, reduces hepatocellular carcinoma (HCC) proliferation. To further delineate MK2206, we sought to investigate the Notch1 pathway and hypothesize that MK2206 treatment will result in Notch1 inhibition with either subsequent or parallel Akt suppression. Methods HCC cell lines were treated with various concentrations of MK2206. Cell proliferation was determined via real-time live cell imaging. Knockdown of Notch1 was used to observe interaction between Notch1 and pAkt. Cell lysates were analyzed via Western blotting for Notch and Akt pathway targets. Results After treatment with MK2206 (up to 2 μM), there was a 60% reduction in cell viability at 48 hours with a concomitant reduction in Notch1 expression. Knockdown of Notch1 in HCC cell lines correlated with reduction in Akt phosphorylation. Conclusions MK2206 inhibits both the PI3-K/Akt and Notch1 pathways. Therefore, further characterization of MK2206 comparing the 2 pathways is warranted and the effect of dual targeting in HCC.</description><identifier>ISSN: 0002-9610</identifier><identifier>EISSN: 1879-1883</identifier><identifier>DOI: 10.1016/j.amjsurg.2015.11.029</identifier><identifier>PMID: 26850133</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Akt ; Blotting, Western ; Carcinoma, Hepatocellular - pathology ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Cell Survival - drug effects ; Clinical trials ; Dual target ; Hepatocellular carcinoma ; Heterocyclic Compounds, 3-Ring - pharmacology ; Humans ; Kinases ; Liver cancer ; Liver Neoplasms - pathology ; MK2206 ; Mortality ; Notch ; Phosphorylation ; Proto-Oncogene Proteins c-akt - antagonists &amp; inhibitors ; Receptor, Notch1 - metabolism ; Signal Transduction - drug effects ; Studies ; Surgery ; Tumors</subject><ispartof>The American journal of surgery, 2016-04, Vol.211 (4), p.755-760</ispartof><rights>Elsevier Inc.</rights><rights>2016 Elsevier Inc.</rights><rights>Copyright © 2016 Elsevier Inc. All rights reserved.</rights><rights>Copyright Elsevier Limited Apr 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-88641e2976d9e29918f4335dad215ba1072a44ba45381a26f6c3ec46ab2ecb163</citedby><cites>FETCH-LOGICAL-c448t-88641e2976d9e29918f4335dad215ba1072a44ba45381a26f6c3ec46ab2ecb163</cites><orcidid>0000-0003-4172-0576 ; 0000-0003-3712-7497</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26850133$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sokolowski, Kevin M., M.D</creatorcontrib><creatorcontrib>Balamurugan, Mariappan, Ph.D</creatorcontrib><creatorcontrib>Kunnimalaiyaan, Selvi, M.S</creatorcontrib><creatorcontrib>Wilson, Jacob, B.S</creatorcontrib><creatorcontrib>Gamblin, Thomas Clark, M.D., M.S., M.B.A., F.A.C.S</creatorcontrib><creatorcontrib>Kunnimalaiyaan, Muthusamy, Ph.D</creatorcontrib><title>Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy</title><title>The American journal of surgery</title><addtitle>Am J Surg</addtitle><description>Abstract Background We have shown that an Akt inhibitor, MK2206, reduces hepatocellular carcinoma (HCC) proliferation. To further delineate MK2206, we sought to investigate the Notch1 pathway and hypothesize that MK2206 treatment will result in Notch1 inhibition with either subsequent or parallel Akt suppression. Methods HCC cell lines were treated with various concentrations of MK2206. Cell proliferation was determined via real-time live cell imaging. Knockdown of Notch1 was used to observe interaction between Notch1 and pAkt. Cell lysates were analyzed via Western blotting for Notch and Akt pathway targets. Results After treatment with MK2206 (up to 2 μM), there was a 60% reduction in cell viability at 48 hours with a concomitant reduction in Notch1 expression. Knockdown of Notch1 in HCC cell lines correlated with reduction in Akt phosphorylation. Conclusions MK2206 inhibits both the PI3-K/Akt and Notch1 pathways. Therefore, further characterization of MK2206 comparing the 2 pathways is warranted and the effect of dual targeting in HCC.</description><subject>Akt</subject><subject>Blotting, Western</subject><subject>Carcinoma, Hepatocellular - pathology</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Cell Survival - drug effects</subject><subject>Clinical trials</subject><subject>Dual target</subject><subject>Hepatocellular carcinoma</subject><subject>Heterocyclic Compounds, 3-Ring - pharmacology</subject><subject>Humans</subject><subject>Kinases</subject><subject>Liver cancer</subject><subject>Liver Neoplasms - pathology</subject><subject>MK2206</subject><subject>Mortality</subject><subject>Notch</subject><subject>Phosphorylation</subject><subject>Proto-Oncogene Proteins c-akt - antagonists &amp; inhibitors</subject><subject>Receptor, Notch1 - metabolism</subject><subject>Signal Transduction - drug effects</subject><subject>Studies</subject><subject>Surgery</subject><subject>Tumors</subject><issn>0002-9610</issn><issn>1879-1883</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNqFkl2L1TAQhoso7nH1JygBb7xpzSRpm3qhLItfsCj4cR3SdLon3bbpJql4_r2p56iwN0JgSHjmncm8k2VPgRZAoXo5FHoawuqvC0ahLAAKypp72Q5k3eQgJb-f7SilLG8qoGfZoxCGdAUQ_GF2xipZUuB8l91-cSMS15OLm0jsvLetjdbNJJ1PLpo9EPy5eAxhe7Qz2eOiozM4juuoPTHaGzu7Sb8ii4s4R6tH4jfJ3nnSrekWtb_GiB2Je_R6OTzOHvR6DPjkFM-z7-_efrv8kF99fv_x8uIqN0LImEtZCUDW1FXXpNCA7AXnZac7BmWrgdZMC9FqUXIJmlV9ZTgaUemWoWmh4ufZi6Pu4t3tiiGqyYatcT2jW4OCuk65tOYsoc_voINb_Zy6-01JkUqUiSqPlPEuBI-9WrydtD8ooGrzRA3q5InaPFEAKnmS8p6d1Nd2wu5v1h8TEvDmCGAaxw-LXgVjcTbYWY8mqs7Z_5Z4fUfBjHa2Ro83eMDw7zcqMEXV120xtr1IY0o7wUr-C0FktN8</recordid><startdate>20160401</startdate><enddate>20160401</enddate><creator>Sokolowski, Kevin M., M.D</creator><creator>Balamurugan, Mariappan, Ph.D</creator><creator>Kunnimalaiyaan, Selvi, M.S</creator><creator>Wilson, Jacob, B.S</creator><creator>Gamblin, Thomas Clark, M.D., M.S., M.B.A., F.A.C.S</creator><creator>Kunnimalaiyaan, Muthusamy, Ph.D</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4172-0576</orcidid><orcidid>https://orcid.org/0000-0003-3712-7497</orcidid></search><sort><creationdate>20160401</creationdate><title>Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy</title><author>Sokolowski, Kevin M., M.D ; Balamurugan, Mariappan, Ph.D ; Kunnimalaiyaan, Selvi, M.S ; Wilson, Jacob, B.S ; Gamblin, Thomas Clark, M.D., M.S., M.B.A., F.A.C.S ; Kunnimalaiyaan, Muthusamy, Ph.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-88641e2976d9e29918f4335dad215ba1072a44ba45381a26f6c3ec46ab2ecb163</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Akt</topic><topic>Blotting, Western</topic><topic>Carcinoma, Hepatocellular - pathology</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Cell Survival - drug effects</topic><topic>Clinical trials</topic><topic>Dual target</topic><topic>Hepatocellular carcinoma</topic><topic>Heterocyclic Compounds, 3-Ring - pharmacology</topic><topic>Humans</topic><topic>Kinases</topic><topic>Liver cancer</topic><topic>Liver Neoplasms - pathology</topic><topic>MK2206</topic><topic>Mortality</topic><topic>Notch</topic><topic>Phosphorylation</topic><topic>Proto-Oncogene Proteins c-akt - antagonists &amp; inhibitors</topic><topic>Receptor, Notch1 - metabolism</topic><topic>Signal Transduction - drug effects</topic><topic>Studies</topic><topic>Surgery</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sokolowski, Kevin M., M.D</creatorcontrib><creatorcontrib>Balamurugan, Mariappan, Ph.D</creatorcontrib><creatorcontrib>Kunnimalaiyaan, Selvi, M.S</creatorcontrib><creatorcontrib>Wilson, Jacob, B.S</creatorcontrib><creatorcontrib>Gamblin, Thomas Clark, M.D., M.S., M.B.A., F.A.C.S</creatorcontrib><creatorcontrib>Kunnimalaiyaan, Muthusamy, Ph.D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sokolowski, Kevin M., M.D</au><au>Balamurugan, Mariappan, Ph.D</au><au>Kunnimalaiyaan, Selvi, M.S</au><au>Wilson, Jacob, B.S</au><au>Gamblin, Thomas Clark, M.D., M.S., M.B.A., F.A.C.S</au><au>Kunnimalaiyaan, Muthusamy, Ph.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy</atitle><jtitle>The American journal of surgery</jtitle><addtitle>Am J Surg</addtitle><date>2016-04-01</date><risdate>2016</risdate><volume>211</volume><issue>4</issue><spage>755</spage><epage>760</epage><pages>755-760</pages><issn>0002-9610</issn><eissn>1879-1883</eissn><abstract>Abstract Background We have shown that an Akt inhibitor, MK2206, reduces hepatocellular carcinoma (HCC) proliferation. To further delineate MK2206, we sought to investigate the Notch1 pathway and hypothesize that MK2206 treatment will result in Notch1 inhibition with either subsequent or parallel Akt suppression. Methods HCC cell lines were treated with various concentrations of MK2206. Cell proliferation was determined via real-time live cell imaging. Knockdown of Notch1 was used to observe interaction between Notch1 and pAkt. Cell lysates were analyzed via Western blotting for Notch and Akt pathway targets. Results After treatment with MK2206 (up to 2 μM), there was a 60% reduction in cell viability at 48 hours with a concomitant reduction in Notch1 expression. Knockdown of Notch1 in HCC cell lines correlated with reduction in Akt phosphorylation. Conclusions MK2206 inhibits both the PI3-K/Akt and Notch1 pathways. Therefore, further characterization of MK2206 comparing the 2 pathways is warranted and the effect of dual targeting in HCC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26850133</pmid><doi>10.1016/j.amjsurg.2015.11.029</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4172-0576</orcidid><orcidid>https://orcid.org/0000-0003-3712-7497</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0002-9610
ispartof The American journal of surgery, 2016-04, Vol.211 (4), p.755-760
issn 0002-9610
1879-1883
language eng
recordid cdi_proquest_miscellaneous_1774530732
source ScienceDirect Journals
subjects Akt
Blotting, Western
Carcinoma, Hepatocellular - pathology
Cell Line, Tumor
Cell Proliferation - drug effects
Cell Survival - drug effects
Clinical trials
Dual target
Hepatocellular carcinoma
Heterocyclic Compounds, 3-Ring - pharmacology
Humans
Kinases
Liver cancer
Liver Neoplasms - pathology
MK2206
Mortality
Notch
Phosphorylation
Proto-Oncogene Proteins c-akt - antagonists & inhibitors
Receptor, Notch1 - metabolism
Signal Transduction - drug effects
Studies
Surgery
Tumors
title Role of Akt inhibition on Notch1 expression in hepatocellular carcinoma: potential role for dual targeted therapy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T03%3A45%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20Akt%20inhibition%20on%20Notch1%20expression%20in%20hepatocellular%20carcinoma:%20potential%20role%20for%20dual%20targeted%20therapy&rft.jtitle=The%20American%20journal%20of%20surgery&rft.au=Sokolowski,%20Kevin%20M.,%20M.D&rft.date=2016-04-01&rft.volume=211&rft.issue=4&rft.spage=755&rft.epage=760&rft.pages=755-760&rft.issn=0002-9610&rft.eissn=1879-1883&rft_id=info:doi/10.1016/j.amjsurg.2015.11.029&rft_dat=%3Cproquest_cross%3E3993006171%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c448t-88641e2976d9e29918f4335dad215ba1072a44ba45381a26f6c3ec46ab2ecb163%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1774843815&rft_id=info:pmid/26850133&rfr_iscdi=true